Company Culture

Discussion in 'Alimera Sciences' started by anonymous, Mar 18, 2017 at 1:52 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I’ll make a prediction that this company won’t be around much longer.... 6 months
    Take it off life support, please.
    Stock is hanging so low.... around 86 cents when RE told us at the National Meeting in March that stock would be at 1.30 by December! Won’t happen! A reverse stock split is much more realistic. Don’t believe the rah rah lies from leaders. It’s just not true. Sales numbers don’t lie and they are slumping. Leaders blame past reps bad mouthing Iluvien as reason for poor sales. Finger pointing to explain lack of sales. Maybe it’s just not a good product and docs don’t want to use it! They don’t like dealing with harmful affects when they don’t have to for products that work fine! Reps have to tell docs how great Iluvien is and take the constant negative push back which is miserable. Alimera is not going to make it out of this slump. Get off the ship before all the life rafts are gone!
     

  2. Alimerawrong

    Alimerawrong Guest

    These are all lies. Alimera is poised to be one of the greatest ophthalmology companies by year 2020. We have a stable experienced sales team, credibility with our customers and a deep pipeline. Obviously this is a future-looking statement so don’t quote me on this.

    The reality is that RE and his bros are hoisted by their own petard....or more like their own r*****. None of these individuals would have a high ranking position at any other company and they are just hoping for a buy-out. And because it’s a boys club only the brown nosers stay and get promoted to VP.

    This company will probably last for more than 6 months, get bought out at a very low price (maybe Eyepoint mostly for the ex-US label) and everyone (except for ex-US folks) will be offloaded like the Xiidra reps at Novartis. Alternatively they stay on the “brink of profitability” and run out of cash and get delisted (probably just one lawsuit away from closing shop).
     
  3. anonymous

    anonymous Guest

    leadership calling former employees to apologize for MH. Are they trying to protect themselves from lawsuits?
     
  4. anonymous

    anonymous Guest

    Very poor leaders in charge lead to multiple lawsuits and that’s been Alimera’s track record which is clearly going to continue. I heard another former employee wants to sue and has good reasons to do it. That ones not MH related. Looks like multiple lawsuits are coming again. This group doesn’t know how to treat people and doesn’t lead. Another former employee told me they left not because of their direct supervisor but because of upper leadership and lack of respect for field staff. It’s a hot mess at Alimera. BTW stock is at 73 cents today and earnings call on the 30th won’t make stock go up!!!
     
  5. anonymous

    anonymous Guest

    Thoughts on the earnings call? I am a current employee and it sounded terrible.
     
  6. anonymous

    anonymous Guest

    Turn out the lights. ALIM is DEAD. Good thing the economy is rolling so you can find another position rather quickly. A con game from the start. DOJ/SEC should be all over DM, the perp of this fraud.
     
  7. anonymous

    anonymous Guest

    When the CEO of a Pharma company doesn’t know the difference between prospective and retrospective on a earnings call, you know you are f*cked!

    RE needs some sales training.
     
  8. anonymous

    anonymous Guest

    This dead duck quit quacking a long time ago ! The trend is not your friend.....
     
  9. anonymous

    anonymous Guest

    It was bad, real bad....RE sounded defeatist from the getgo. Reps leaving for pastures greener, does not account for all of the reduction in sales in the US. Customers not putting iluvien into routine treatment is the key issue, it is still reserved as a treatment of final resort because customers want to give monthly injections and make money.
    It was inevitable that the share price was going to take a hammering after that call because of the poor US sales performance.
    It’s gonna get a lot worse, before it gets better.
     
  10. anonymous

    anonymous Guest

    What’s better? Like out of the slump or a buy out?
     
  11. anonymous

    anonymous Guest

    Going Going Gone !
     
  12. anonymous

    anonymous Guest

    All the life rafts are gone. Shareholder equity has gone from $21.17 in 2017 to 0.65 today. They are broke with no help in sight. Their product is a dud. Chunk of plastic in the eye will NEVER sell.
     
  13. anonymous

    anonymous Guest

    if you are still at Alimera, we all have to get serious about finding our next job now before the end of the year when less job openings / interviews happen. Don’t wait. Update resume and get in touch with recruiters ASAP. If you still have ALIM stock, better cash out before it’s worth 0. The writing is on the wall.
    They are trying to sell Alimera. Failed merger last December. Still trying to offload company so top dogs get payout. Staff are the ones who will suffer because no money for severance when it’s all over. Titanic is sinking. Don’t stand on deck listening to the violins play sweet music to distract you from reality.
     
  14. anonymous

    anonymous Guest

    There is no better. It’s over. Done. Checkmate. Time to fly.
     
  15. anonymous

    anonymous Guest

    Chunk of plastic that stays in Eye forever and causes cataract and increased IOP and doesn’t last 3 years — is a dud product.
     
  16. anonymous

    anonymous Guest

    brolucizumab launch expected at year end will further erode Iluvien sales as there will be another long term DME treatment without side effects. If you think things look bad or dark now, you haven’t seen how dark it will be. By 2020, everyone will see 20/20 clear that Alimera doesn’t have a future. There is no way to get better.
     
  17. anonymous

    anonymous Guest

    brolucizumab launch expected at year end will further erode Iluvien sales as there will be another long term DME treatment without side effects. If you think things look bad or dark now, you haven’t seen how dark it will be. By 2020, everyone will see 20/20 clear that Alimera doesn’t have a future. There is no way to get better.
     
  18. anonymous

    anonymous Guest

    and the ALIM stock is now 50 cents a share..... 2 quarters will buy you a share of ALIM....
     
  19. anonymous

    anonymous Guest

    What a crass thing to say... is AC on the cafepharma message board again?
     
  20. anonymous

    anonymous Guest

    A crass reaction to being in a shitty situation at a terrible company. Must be awful when still at Alimera watching the company go belly up. Alimera fought long and hard but the battle is lost and it’s hard to accept this reality.

    Stock now at 49 cents. Not even 2 quarters....